Radiotherapy
Radiation48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.
Other names: Radiation
NCT Number: NCT00287196
This trial seeks to establish the role of post-operative radiotherapy in patients who have had surgery for melanoma involving lymph nodes and who are at high risk of recurrence.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
This is a randomised phase III trial which is being performed on patients at high risk of local recurrence after having a lymphadenectomy for stage 3 melanoma. The control arm is surgery alone with radiotherapy reserved for those who recur. The study arm is surgery plus post-operative radiotherapy. All 3 major node sites are eligible. The radiation dose administered is 48Gy in 20 fractions. It is likely to be the only study of its kind ever performed. The target is 230 patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.
Other names: Radiation
Time frame: Final analysis will occur when all patients have had 1 year follow up. (approx. 7 years after start of trial)
Time frame: Final analysis will occur when all patients have had 1 year follow up. (approx. 7 years after start of trial)
Time frame: Final analysis will occur when all patients have had 1 year follow up. (approx. 7 years after start of trial)
Time frame: Interim analysis will occur on annual basis.
Time frame: Final analysis will occur when all patients have had 1 year follow up. (approx. 7 years after start of trial)
Trans Tasman Radiation Oncology Group
Other
Randomised Clinical Trial of Surgery Versus Surgery Plus Adjuvant Radiotherapy for Regional Control in Patients With Completely Resected Macroscopic Nodal Metastatic Melanoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03236935
Bronchial Neoplasms, Carcinoma
Houston, Texas, United States
View Trial DetailsNCT07427953
Drug-Induced Retinopathy, Malignant Melanoma
Ljubljana, Slovenia
View Trial DetailsNCT07436390
Malignant Melanoma, Melanoma
Ljubljana, Slovenia
View Trial DetailsNCT07431489
MEK Inhibitor-Associated Retinopathy, Malignant Melanoma
Ljubljana, Slovenia
View Trial Details